Innovative AI platforms are reshaping biological modeling, improving insights into cell behavior and protein dynamics essential for drug discovery. The GREmLN model developed by Columbia University and Chan Zuckerberg Initiative captures gene regulatory networks with enhanced accuracy using graph-based neural networks, outperforming existing large language models in cellular state prediction. Separately, Microsoft Research introduced BioEmu, a generative deep learning system that rapidly models protein equilibrium ensembles, enabling high-speed prediction of diverse conformations to inform drug design efficiently. These advances reflect a growing trend in leveraging AI for complex biological processes.